HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumer Health Fraud: Collidial Silver A Pandemic Repeat Offender

Executive Summary

COVID-19 makes silver a gift that keeps on giving for US regulators with another business closed by court order; Seattle area naturopath charged with selling misbranded drug as a virus prevention; FTC reaches settlements with operators of “free trial” schemes for cosmetics and supplements; FDA announces criminal convictions of two men who defrauded the agency by misbranding steroid drugs they sold OTC.

You may also be interested in...



Utah Silver Supplement Provider's COVID-19 Remedy Claim No Surprise To Authorities

Federal court issues TRO blocking My Doctor Suggests, GP Silver and their  owner, Gordon Pedersen, from continuing to sell or distribute silver colloidal products for the diagnosis, cure, mitigation, treatment or prevention of any disease.

State Agencies Sharpen Supplement Market Oversight During Pandemic, With Industry's Thanks

"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III.  He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.

Bogus Coronavirus Claims For Silver, Essential Oils, Herbalist's Tea 'Protocol' Plus A Price Discount

Obviously unsubstantiated claims on how the products either prevent or cure the virus didn’t escape FDA and FTC's attention -- they warned seven firms attempting to capitalize on consumer fears. They warnings are the “first step” and they plan to enforce action against companies that continue to market products with treatment claims.

Related Content

Topics

UsernamePublicRestriction

Register

SC142283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel